<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04629937</url>
  </required_header>
  <id_info>
    <org_study_id>CHRO 2020-20</org_study_id>
    <nct_id>NCT04629937</nct_id>
  </id_info>
  <brief_title>Evaluation of Whole-body CZT Camera in Gated Tomographic Radionuclide Angiography</brief_title>
  <acronym>STARGAC</acronym>
  <official_title>Clinical Evaluation of a Multipurpose CZT Camera in Gated Tomographic Radionuclide Angiography: a Head to Head Comparison With a Cardiac Dedicated CZT Device</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Régional d'Orléans</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Régional d'Orléans</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Tomographic radionuclide angiography (or blood pool) is a reproducible method to evaluate&#xD;
      left ventricular ejection fraction that is needed during oncological treatments or to&#xD;
      evaluate cardiopathies.&#xD;
&#xD;
      Cardiac-dedicated CZT systems allowed dose or time reduction. Multipurpose CZT cameras have&#xD;
      not yet been evaluated in this indication. Moreover, the impact of attenuation correction is&#xD;
      not known.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Tomographic radionuclide angiography is a simple, rapid and reproducible method of cardiac&#xD;
      function measurement, including left (LVEF) and right (RVEF) ventricular ejection fractions.&#xD;
&#xD;
      In addition to cardiological indications, this examination is often performed as part of&#xD;
      cardiac toxicity screening during the various oncological treatments. This indication is all&#xD;
      the more true since the arrival of CZT gamma cameras dedicated to cardiological studies has&#xD;
      made it possible to reduce injected activities, as well as examination times.&#xD;
&#xD;
      The multipurpose CZT camera allows tomoscintigraphic acquisitions to be carried out using CZT&#xD;
      technology as well. Unlike the CZT gamma cameras dedicated to cardiological studies, this&#xD;
      system can be used for the exploration of different organs, and also allows the realization&#xD;
      of CT slices for attenuation correction.&#xD;
&#xD;
      Patients included in this study will be double scanned both on a dedicated cardiac CZT camera&#xD;
      and on multipurpose CZT camera, with CT. LVEF and RVEF will be then compared.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 30, 2020</start_date>
  <completion_date type="Anticipated">May 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 30, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>All patients will undergo SPECT acquisitions with both multipurpose CZT camera and cardiac dedicated CZT camera.</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assessment of left and right ventricular volumes and ejection fraction.</measure>
    <time_frame>Day 0</time_frame>
    <description>Automatic quantification of left and right ventricular volumes, left ventricle ejection fraction (LVEF) and right ventricle ejection fraction (RVEF) using BPGs software (Cedars-Sinai Medical Center, Los Angeles, USA).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of left and ventricular volumes and ejection fraction with attenuation correction.</measure>
    <time_frame>Day 0</time_frame>
    <description>Assessment of an attenuation map from low dose CT data. Automatic quantification of left and right ventricular volumes, LVEF and RVEF using BPGs software (Cedars-Sinai Medical Center, Los Angeles, USA).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">81</enrollment>
  <condition>Cardiac Function</condition>
  <arm_group>
    <arm_group_label>SPECT acquisitions</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients will undergo SPECT acquisitions with both multipurpose CZT camera and cardiac dedicated CZT camera.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>SPECT acquisitions</intervention_name>
    <description>All patients will undergo SPECT acquisitions with both multipurpose CZT camera and cardiac dedicated CZT camera.</description>
    <arm_group_label>SPECT acquisitions</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients referred to our Nuclear Medicine department for evaluation of cardiac&#xD;
             function.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients treated with chemotherapy within 12 days.&#xD;
&#xD;
          -  Under 18 years old patients.&#xD;
&#xD;
          -  Pregnant women or at risk of pregnancy.&#xD;
&#xD;
          -  Breast feeding.&#xD;
&#xD;
          -  Painful patients.&#xD;
&#xD;
          -  Patients under guardianship.&#xD;
&#xD;
          -  Patients in whom a standard examination is not feasible (agitation).&#xD;
&#xD;
          -  Patients who do not benefit from a social security system&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frédérique THIBAULT, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHR d'Orléans</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Aurélie DESPUJOLS</last_name>
    <phone>+33238744071</phone>
    <email>aurelie.despujols@chr-orleans.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Elodie POUGOUE TOUKO</last_name>
    <phone>+33238744086</phone>
    <email>elodie.pougoue-touko@chr-orleans.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHR d'Orleans</name>
      <address>
        <city>Orléans</city>
        <zip>45067</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frédérique THIBAULT, Dr</last_name>
      <phone>+33238575078</phone>
      <email>frederique.thibault@chr-orleans.fr</email>
    </contact>
    <contact_backup>
      <last_name>Matthieu BAILLY, Dr</last_name>
      <phone>+33238575078</phone>
      <email>matthieu.bailly@chr-orleans.fr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018 Nov;68(6):394-424. doi: 10.3322/caac.21492. Epub 2018 Sep 12. Erratum in: CA Cancer J Clin. 2020 Jul;70(4):313.</citation>
    <PMID>30207593</PMID>
  </reference>
  <reference>
    <citation>Carver JR, Shapiro CL, Ng A, Jacobs L, Schwartz C, Virgo KS, Hagerty KL, Somerfield MR, Vaughn DJ; ASCO Cancer Survivorship Expert Panel. American Society of Clinical Oncology clinical evidence review on the ongoing care of adult cancer survivors: cardiac and pulmonary late effects. J Clin Oncol. 2007 Sep 1;25(25):3991-4008. Epub 2007 Jun 18. Review.</citation>
    <PMID>17577017</PMID>
  </reference>
  <reference>
    <citation>Curigliano G, Cardinale D, Suter T, Plataniotis G, de Azambuja E, Sandri MT, Criscitiello C, Goldhirsch A, Cipolla C, Roila F; ESMO Guidelines Working Group. Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines. Ann Oncol. 2012 Oct;23 Suppl 7:vii155-66.</citation>
    <PMID>22997448</PMID>
  </reference>
  <reference>
    <citation>Garcia EV, Faber TL, Esteves FP. Cardiac dedicated ultrafast SPECT cameras: new designs and clinical implications. J Nucl Med. 2011 Feb;52(2):210-7. doi: 10.2967/jnumed.110.081323. Epub 2011 Jan 13. Review.</citation>
    <PMID>21233190</PMID>
  </reference>
  <reference>
    <citation>Garcia EV. Are SPECT measurements of myocardial blood flow and flow reserve ready for clinical use? Eur J Nucl Med Mol Imaging. 2014 Dec;41(12):2291-3. doi: 10.1007/s00259-014-2924-2.</citation>
    <PMID>25311927</PMID>
  </reference>
  <reference>
    <citation>Slomka PJ, Berman DS, Germano G. New cardiac cameras: single-photon emission CT and PET. Semin Nucl Med. 2014 Jul;44(4):232-51. doi: 10.1053/j.semnuclmed.2014.04.003. Review.</citation>
    <PMID>24948149</PMID>
  </reference>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>November 10, 2020</study_first_submitted>
  <study_first_submitted_qc>November 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 16, 2020</study_first_posted>
  <last_update_submitted>February 10, 2021</last_update_submitted>
  <last_update_submitted_qc>February 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>SPECT</keyword>
  <keyword>gated tomographic radionuclide angiography</keyword>
  <keyword>Multipurpose CZT camera</keyword>
  <keyword>left ventricle ejection fraction</keyword>
  <keyword>Radionuclide angiography</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

